Objective: To report a massive increase in subcutaneous insulin requirements following spinal cord injury in a type 1 diabetic and how it was managed over a 22-month period with pramlintide.
requirements. Total daily intravenous insulin requirement was determined to be 259 U (1.96 U/kg). The patient was started on pramlintide. 22 months after the onset of pramlintide treatment his total daily dose of subcutaneous insulin decreased to 150 U 
Case Report
The patient is a 43-year-old male diagnosed with type 1 diabetes mellitus (T1DM) at age 18. His initial office visit was 5 years after diagnosis in 1999. He returned to the practice in 2005 at age 30. At that time, he had no end organ complications. On initial examination he weighed 88.6 kg (195 lbs). He was treated with multiple daily injections of insulin with a total daily dose 81 units (U) (0.91 U/kg). His HbA1c was 8.0% (64 mmol/mol). After the initial visit, over the next few years he had two episodes of diabetic ketoacidosis precipitated by intercurrent illness or often episodes were precipitated by binge drinking of vodka. After 15 years of diabetes there was no evidence of diabetic retinopathy. After a prolonged rehabilitation of 18 months, he was transferred to an intermediate care facility before being discharged to home. Upon his return home, insulin requirements were significantly increased and he became extremely focused on his diabetic care and blood sugar control. TDD was up to 600 U (4 U/kg). His diet did not change significantly after returning home, as he did not require parenteral or enteral feeding during or after rehabilitation. As an adjunctive pharmacological therapy, the patient was started on 15 µg of pramlintide before each meal. The medication was well tolerated and over the following year he gradually increased his dose to 240 µg per day. 22 months after starting pramlintide, his weight had decreased to 115 kg (254 lbs). His subcutaneous TDD of insulin decreased to 150 U (1.3 U/kg), which approached the same U/kg he had in 2005 at age 30 (0.91 U/kg). His most recent HbA1c was 4.4% (25 mmol/mol). There were no biochemical or physical exam findings indicative of anemia.
Discussion
We have described a T1DM patient who sustained an infectious spinal cord injury (SCI) and tetraplegia, resulting in a massive increase in subcutaneous insulin requirements. The addition of preprandial pramlintide to his treatment regimen allowed DOI:10.4158/ACCR-2019-0461 © 2020 AACE. the patient to decrease his TDD and lose 19 kg (41 lbs) over a period of 22 months, greatly increasing his quality of life. At the peak of the patient's insulin requirements, it was noted that his IV TDD was 341 U lower than his subcutaneous requirements.
Variation of injection sites did not reduce his subcutaneous TDD. It was suspected that spinal cord damage relating to autonomic efferent pathways impaired absorption of insulin depots in the subcutaneous space. One recent study (4) has implicated autonomic dysregulation in SCI patients as a primary mechanism of subcutaneous malabsorption using insulin and acetylcholine iontophoresis. Decreased sympathetic innervation to the endothelial vascular bed results in downregulation of α and β adrenergic receptors and endothelial dysfunction (4) . Without sympathetic outflow, it is possible that nitric oxide (NO) levels remain unopposed, leading to desensitization of guanylyl cyclase, the NO receptor. Indeed, NO synthase is upregulated in SCI, acutely leading to elevated microvascular permeability (5) , but chronic elevation leads to receptor desensitization (6) . At the moment, however, there is a paucity of human subject literature on the effects of SCI on subcutaneous absorption of insulin. Pramlintide is a soluble analogue of amylin, which is released from healthy islet β-cells with insulin at a ratio of 1:15 (amylin to insulin) (7) . Amylin is an important regulator of post-prandial glycemic control and is deficient in T1DM patients (8) . By decreasing glucagon secretion, delaying gastric emptying, and inducing satiety, pramlintide has been shown to decrease glycated hemoglobin, body weight, and insulin requirements in T1DM patients (9) .
Pramlintide may be an especially effective treatment in the cervical SCI population for a number of reasons. Subcutaneous absorption may be less affected by autonomic denervation due to its smaller size and linear structure compared to insulin aspart; 3.9 kDa compared to 5.8 kDa, respectively. In addition, amylin and its analogues are able to readily cross the blood-brain barrier, allowing it to influence energy homeostasis without intact autonomic afferents (10) . However, to determine the exact mechanism as it relates to our patient, further objective measures are required.
Radiolabeled insulin studies from multiple absorption sites before and after beginning pramlintide would be necessary to make definitive claims regarding the central and peripheral effects of pramlintide in our patient. Due to our limited resources at our private practice, these measures were not able to be performed, limiting our ability to DOI:10.4158/ACCR-2019-0461 © 2020 AACE. confidently state the relationship between the literature and the patient case reported above.
Following his SCI, the patient became highly motivated and vigilant regarding his diabetic care, sometimes nearing the point of hypoglycemia. The patient never had any severe hypoglycemic events and was cared for at all times by a home health nurse. Impaired sympathetic function and insulin absorption make over medication and hypoglycemia more likely in a tetraplegic patient. Patients will have difficulty detecting episodes of hypoglycemia without sympathetically-mediated physiological signs, such as sweating and palpitations. Slowed absorption may also lead to double-dosing or unnecessary increases in insulin dose. A combination of these two factors are likely the cause of our patient's glycated hemoglobin of 4.4% (25 mmol/mol). Diabetes management and insulin dosing has continued to be very important to our patient, granting him a sense of autonomy and control. As a result of his extremely tight glycemic control, his measured TDD may be higher than his physiological need. The patient was not interested in trying pump therapy or continuous glucose monitoring, making patient and caregiver education imperative.
